KlothovsThymalin

Klotho is a single-pass transmembrane protein primarily expressed in the kidney, parathyroid gland, and choroid plexus, with a soluble form (s-Klotho) cleaved from the membrane and circulating systemically as an endocrine factor. It exists in three forms — alpha-Klotho (the most studied, anti-ageing form), beta-Klotho (which partners with FGF21), and gamma-Klotho — each with distinct receptor partnerships and tissue effects.

At the receptor level, alpha-Klotho is the obligate co-receptor for fibroblast growth factor 23 (FGF23), enabling FGF23 to bind and activate FGFR1 receptors in the kidney to regulate phosphate excretion. This makes Klotho a central node in mineral metabolism. Beyond this canonical role, soluble Klotho exerts numerous endocrine effects: it inhibits the IGF-1/insulin signalling pathway (a conserved longevity mechanism shared with caloric restriction), enhances expression of antioxidant enzymes via FoxO transcription factor activation, suppresses Wnt signalling (reducing stem cell exhaustion), inhibits TGF-beta signalling (preventing fibrosis), and blocks NF-kB and NLRP3 inflammasome activation (reducing inflammaging).

The ageing phenotype connection is striking: mice lacking Klotho develop multi-organ ageing — atherosclerosis, osteoporosis, skin atrophy, cognitive decline — within weeks of birth, while mice with elevated Klotho expression live up to 30% longer than controls. In humans, circulating Klotho levels decline with age, and lower levels associate with increased mortality and chronic disease risk in observational studies. Recombinant alpha-Klotho is in early clinical development as a potential therapy for chronic kidney disease, cognitive decline, and broader age-related diseases. The 2026 research wave around Klotho has positioned it as one of the most promising single-protein interventions in the longevity field, though no therapeutic Klotho product is yet approved for human use.

Thymalin is a complex of short peptides extracted from bovine thymus glands, representing the biologically active fraction of thymic hormones. The thymus gland is the primary organ of T-cell maturation — bone marrow-derived T-cell precursors migrate to the thymus where they undergo positive and negative selection, emerging as mature, immunocompetent CD4+ helper and CD8+ cytotoxic T cells. The thymus produces a suite of peptide hormones that guide this maturation process, and Thymalin contains a mixture of these bioactive peptides.

The peptide complex acts at multiple points in the immune system. It promotes the differentiation of pre-T cells into mature T-cell subsets, restoring the CD4/CD8 ratio toward normal values (typically 1.5-2.5:1 in healthy individuals). It enhances natural killer (NK) cell cytotoxic activity, which is critical for immune surveillance against virus-infected and neoplastic cells. It modulates cytokine production — generally promoting a balanced Th1/Th2 response rather than driving either extreme — and enhances macrophage phagocytic capacity.

The relevance to aging is direct: the thymus undergoes progressive involution (shrinkage) beginning at puberty, and by age 60-70, most thymic tissue has been replaced by fat, with minimal residual T-cell educating capacity. This thymic involution is a major driver of immunosenescence — the age-related decline in immune function that increases susceptibility to infections, cancers, and autoimmune conditions while reducing vaccine responsiveness. Thymalin aims to pharmacologically replace the thymic peptide signals lost through involution, partially restoring the immune system's ability to produce new, functional T cells. Research from the Khavinson group has reported that Thymalin treatment in elderly patients was associated with reduced mortality and improved immune markers over long-term follow-up, though these studies require independent replication in Western clinical settings.